Clinical trials: Chronic Obstructive Pulmonary
Chronic Obstructive Pulmonary Disease
Uphill Walking as Exercise for COPD Patients
This study is designed to provide preliminary information regarding how to improve pulmonary rehabilitation for persons with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT04026529
- Testing
- walking on incline or walking at increasing speed
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- VA Office of Research and Development
Pulmonary Disease, Chronic Obstructive
OTIVACTO Regional Center Vienna (RCV) Non-Interventional Study (NIS)
Real-world data on the effects of a fixed-dose combination Long-acting beta agonists + long-acting antimuscarinic agent (LABA+LAMA) therapy with tiotropium and olodaterol administered in a single device, in COPD patients who need…
- Trial name
- NCT02719639
- Where
- 9 sites in Austria, Czechia and 7 more
- Volunteers
- 7,443 people
- Sponsor
- Boehringer Ingelheim
Copd
Optimizing Self-management COPD Treatment Through the American Lung Association Helpline
Although self-management treatment improves quality of life among individuals with COPD, there is limited understanding of which elements of treatment are most effective.
- Trial name
- NCT05106257
- Testing
- Self-management education (short), Ground-based walking training, Inhaler training
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Rush University Medical Center
COPD
A Home-based Module to Promote Mindful Breathing Awareness for COPD Patients
The purpose of this study is to develop a mindful breathing module to an already effective and developed home based rehabilitation program for guiding COPD patients in a mindful breathing practice and further palliate…
- Trial name
- NCT04517500
- Testing
- Home-based pulmonary rehabilitation program, Mindful breathing module, Health coaching
- Where
- 2 sites in United States
- Volunteers
- 99 people
- Sponsor
- Mayo Clinic
COPD
A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
This is a randomized, double-blind, placebo-controlled, parallel arm study. The study population will consist of subjects, 35 to 75 years of age, with a diagnosis of moderate to severe COPD per Global Initiative for Chronic…
- Trial name
- GOLDEN-2 (NCT01706536)
- Testing
- EP-101 12.5 mcg, EP-101 25 mcg, EP-101 50 mcg
- Where
- 26 sites in United States
- Volunteers
- 275 people
- Sponsor
- Sunovion Respiratory Development Inc.
Respiratory Insufficiency, Obesity Hypoventilation Syndrome
Juno Perth Clinical Trial
This study is to evaluate the efficacy of a new therapy (Automatic Expiratory Positive Airway Pressure with intelligent Volume Assured Pressure Support (AutoEPAP iVAPS)) designed to treat respiratory insufficiency, respiratory…
- Conditions
- Respiratory Insufficiency, Obesity Hypoventilation Syndrome, Chronic Obstructive Pulmonary Disease (COPD), Neuromuscular Disease
- Trial name
- NCT02317042
- Testing
- Juno
- Where
- 2 sites in Australia
- Volunteers
- 25 people
- Sponsor
- ResMed
Pulmonary Disease, Chronic Obstructive
Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 2
A randomized, placebo-controlled, double-blind, parallel group, multi-center study to assess the safety and efficacy of tiotropium bromide (18 µg) delivered via the HandiHaler® in Chronic Obstructive Pulmonary Disease (COPD)…
- Trial name
- NCT01662986
- Testing
- tiotropium bromide
- Where
- 50 sites in United States
- Volunteers
- 79 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
Efficacy and Safety Study of Symbicort® Turbuhaler® Versus Oxis® Turbuhaler® in Chronic Obstructive Pulmonary Disease (COPD) Patients
The primary purpose of the study is to investigate if Symbicort is more effective than Oxis in increasing forced expiratory volume in one second (FEV1), measured at the clinics, in patients with COPD.
- Trial name
- SUMIRE (NCT01069289)
- Testing
- Budesonide/formoterol (Symbicort Turbuhaler), Formoterol (Oxis Turbuhaler)
- Where
- 119 sites in India, Japan and 7 more
- Volunteers
- 1,293 people
- Sponsor
- AstraZeneca
Traumatic Brain Injury
A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy for the Treatment of Traumatic Brain Injury and Hypoxic-Ischemic Encephalopathy
This study aims to determine the safety of HB-adMSC infusion and treatment effects of HB-adMSC infusion on brain structure, neurocognitive/functional outcomes, and neuroinflammation after subacute and chronic neurological injury…
- Trial name
- NCT04063215
- Testing
- HB-adMSCs
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Hope Biosciences LLC
Partial-thickness Burn, Ulcer
NPWT PRO vs KCI Ulta® NPWT and to Compare NPWT PRO vs NPWT PRO With Simultaneous Irrigation on Wound Healing
This study is designed to assess the efficacy and economics of two NPWT (negative pressure wound therapy) branded devices of wound healing outcomes.
- Trial name
- NCT02519621
- Testing
- NPWT PRO without irrigation, NPWT PRO with irrigation, KCI Ulta
- Where
- 2 sites in United States
- Volunteers
- 90 people
- Sponsor
- Larry Lavery
Chronic Obstructive Pulmonary Disease (COPD)
A Clinical Study to Investigate if a Single Dose of an Approved Drug Product (Glycopyrrolate Inhalation Solution) Reduces Trapped Air in the Lungs of Participants With Chronic Obstructive Pulmonary Disease.
A clinical study to investigate if a single dose of an approved drug product (glycopyrrolate Inhalation Solution) reduces trapped air in the lungs of participants with chronic obstructive pulmonary disease.
- Trial name
- NCT04155047
- Testing
- Glyocopyrrolate Inhalation Solution administered by Magnair
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Sunovion Respiratory Development Inc.
Pulmonary Disease, Chronic Obstructive
A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 and GSK573719 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this 52-week study is to evaluate the long-term safety (in terms of adverse events, COPD exacerbations, laboratory, ECG, and Holter findings, vital signs, use of rescue medication and lung function) of…
- Trial name
- COPD nDPI (NCT01316887)
- Testing
- 125/25 mcg once-daily GSK573719/GW642444, 125mcg once-daily GSK573719
- Where
- 54 sites in United States, Chile and 4 more
- Volunteers
- 563 people
- Sponsor
- GlaxoSmithKline
Anemia, Iron-Deficiency, Kidney Failure, Chronic
Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients
This study compares the effect of Ferrlecit® (a form of intravenous iron) to ferrous sulfate (a form of oral iron) in treating anemia and iron deficiency in chronic kidney disease patients who are not receiving erythropoietic…
- Trial name
- NCT00224055
- Testing
- Sodium Ferric Gluconate Complex in Sucrose Injection, Ferrous sulfate tablets
- Where
- 24 sites in United States, Puerto Rico
- Volunteers
- 89 people
- Sponsor
- Watson Pharmaceuticals
Chronic Graft-versus-host Disease
Daily IL-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease
Chronic GVHD is a medical condition that may occur after a bone marrow, stem cell or cord blood transplant. The donor's immune system may recognize the your body (the host) as foreign and attempt to 'reject' it.
- Trial name
- NCT01366092
- Testing
- Interleukin-2
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- Dana-Farber Cancer Institute
Chronic Obstructive Pulmonary Disease
Mechanistic Study of the Effect of Itepekimab on Airway Inflammation in Patients With COPD
This study was an exploratory, two-part, 12-week, Phase 2a study evaluated the mechanism of action of Itepekimab (anti-IL-33-mAb) and its impact on airway inflammation in former and current smokers with COPD, aged 40 to 70 years.
- Trial name
- AERIFY-3 (NCT05326412)
- Testing
- Itepekimab SAR440340
- Where
- 23 sites in United States, Belgium and 5 more
- Volunteers
- 49 people
- Sponsor
- Sanofi
Pulmonary Disease, Chronic Obstructive
A 24 Week Efficacy Study of Inhaled Umeclidinium (UMEC) in Patients of Chronic Obstructive Pulmonary Disease (COPD) Using a Novel Dry Powder Inhaler (NDPI)
Studies to date provides substantial evidence for the effectiveness for UMEC 62.5 microgram (mcg) as a long term maintenance therapy for the treatment of COPD; this study further evaluates the efficacy and safety of UMEC 62.5 mcg…
- Trial name
- NCT02184611
- Testing
- Umeclidinium bromide
- Where
- 26 sites in China, South Korea
- Volunteers
- 308 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease, Chronic Bronchitis
The Effects of Tiotropium on the Cough Reflex in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Does tiotropium effect the cough reflex in patients with COPD and chronic bronchitis.
- Trial name
- NCT00870896
- Testing
- Tiotropium
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- ThomasTruncale
COPD
Effect of Brovana and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD)
This will be a double-blind crossover trial in 20 patient with stable COPD. Data from this study will provide proof-of-concept information on whether the (anticipated) additional bronchodilator effect of Brovana added to…
- Trial name
- NCT00773786
- Testing
- Arformoterol (Brovana)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Trinity Health Of New England
Pulmonary Disease, Chronic Obstructive
A Study to Investigate the Association of Real-world Sensor-derived Biometric Data With Clinical Parameters and Patient-reported Outcomes for Monitoring Disease Activity in Patients With COPD
The purpose of this multicenter, prospective cohort study is to investigate the correlation of real-world sensor-derived biometric data obtained via a wearable device with clinical parameters and patient-reported outcomes (PROs)…
- Trial name
- NCT05655832
- Testing
- Vivalink wearable device
- Where
- 11 sites in Germany
- Volunteers
- 77 people
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
COPD
Efficacy and Safety of QMF149 vs. Salmeterol Xinafoate/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)
To compare the efficacy, safety and pharmacokinetics of QMF149 delivered via Concept1 to salmeterol xinafoate/fluticasone propionate delivered via Accuhaler in adult patients with COPD
- Trial name
- NCT01636076
- Testing
- QMF149, Salmeterol
- Where
- 115 sites in Australia, Belgium and 16 more
- Volunteers
- 629 people
- Sponsor
- Novartis Pharmaceuticals